Report of the Director and

Financial Statements for the Year Ended 31 December 2012

for

Starlims Europe Limited

THURSDAY

#293

A28 05/09/2013 COMPANIES HOUSE

Contents of the Financial Statements for the Year Ended 31 December 2012

	Page
Company Information	1
Report of the Director	2
Report of the Independent Auditors	5
Profit and Loss Account	7
Balance Sheet	8
Notes to the Financial Statements	9
Trading and Profit and Loss Account	14

Company Information for the Year Ended 31 December 2012

DIRECTOR.

Mr Thomas Craig Freyman

SECRETARY

Mr Elian Robert Winstanley

REGISTERED OFFICE

2nd Floor, Crossgate House

Cross Street

Sale Cheshire M33 7FT

REGISTERED NUMBER

03422264 (England and Wales)

AUDITORS

Bentleys

Chartered Accountants

Statutory Auditor

Hazlemere

70 Chorley New Road

Bolton Lancashire BL1 4BY

BANKERS

The Royal Bank of Scotland plc

Scotland Corporate Service Centre

Audits Team

1st Floor **Drummond House**

1 Redheughs Avenue

EDINBURGH EH12 9JN

Report of the Director for the Year Ended 31 December 2012

The director presents his report with the financial statements of the company for the year ended 31 December 2012

PRINCIPAL ACTIVITY

The principal activity of the company in the year under review was that of the sale and support of Laboratory Software Systems

REVIEW OF BUSINESS

Starlims Technologies was acquired by Abbott pharmaceuticals in March 2010 Since this acquisition Starlims Europe has seen significant growth in headcount and investment. The backing of Abbott has led to the ability for Starlims to win some major deals in 2010 and 2011, significantly, Pepsico Inc, Scottish Police and on-going work with Syngenta.

In 2012 STARLIMS Europe Ltd made the decision to move to new offices. Premises were identified in Sale, Manchester and plans developed and implemented for the fit out of the new offices. STARLIMS Europe occupied the premises on 7th January 2013.

STARLIMS Technologies Ltd is a leading provider of laboratory information management systems. (LIMS), with over 20 years of LIMS experience. The Company's flagship product, STARLIMS(R), improves the reliability of laboratory sampling processes, supports compliance with domestic and international regulations and industry standards, and provides comprehensive reporting, monitoring and analysis capabilities STARLIMS software is used for quality assurance and control, testing and monitoring, and research and development in government, manufacturing and life sciences organisations. With operations in the United States, Canada, the United Kingdom, Israel and Hong Kong, the company serves over 500 organisations in 40 countries. For more information, please see http://www.starlims.com.

Revenues are generated from the sale of perpetual licences to use STARLIMS, software maintenance and related professional services. Our customers generally enter into a standard licence and services agreement with us, under which they are granted a perpetual, non-exclusive licence to use STARLIMS software and are offered the right to be able to buy annual maintenance that provides updates and upgrades to our software as they become available. STARLIMS offices offer professional services, which include consulting, implementation, training and technical support.

The adaptable nature of our software allows us to serve a wide range of industries, including pharmaceutical, agricultural, food and beverage, oil and gas, environmental, chemical, forensics and cosmetics. Of particular note is the Company's increasing success in the public health and clinical sectors worldwide, including a number of ongoing information management system contracts within the NHS.

There have been no exceptional or abnormal transactions during the year. The Group has internal benchmarks and key performance indicators (KPI's) that are commercially sensitive and not available for disclosure in the public domain.

Standard accounting ratios and KPI's can be abstracted from the accounts

DIVIDENDS

No dividends will be distributed for the year ended 31 December 2012

FUTURE DEVELOPMENTS

STARLIMS's vision is to integrate all the information a laboratory creates into a single, web-based platform, while providing the means to manage a wide range of laboratory processes and workflows. Following this strategy, the Group launched an entirely web-based LIMS as early as 2006, and are regularly adding strategic capabilities to that powerful platform. In March 2008, we introduced STARLIMS SDMS, an integrated Scientific Data Management System solution capable of parsing and managing unstructured data together with structured (LIMS) data. Leveraging these two technologies, we made another step towards a unified platform for the paperless laboratory by developing the STARLIMS Electronic Notebook, launched in March 2009. Future developments include creating a version 11 technology that will allow Starlims to support tablet and mobile applications.

Report of the Director for the Year Ended 31 December 2012

STARLIMS has identified a major opportunity in the area of Health Pathology systems with a particular emphasis on the UK NHS Existing suppliers of these systems have not responded well to changing technology or user needs, and many systems already in place are coming up for renewal STARLIMS received approval from Abbott to invest in the development of a system to meet the needs of these clients. A team has been established in the UK which, together with resources in the US, will develop a product to meet these needs. This product will be based on the existing Clinical product.

The Group places considerable emphasis on research and development to expand the capabilities of our existing products and technology, to develop new products, and to improve our existing technologies and capabilities. We believe that our future success will depend upon our ability to maintain our technological leadership, to enhance our existing products and technology, and to introduce on a timely basis new commercially viable products and technology addressing the needs of our customers. As part of our product development process, we seek to maintain close relationships with our customers to identify market needs and to define appropriate product specifications.

DIRECTOR

Mr Thomas Craig Freyman held office during the whole of the period from 1 January 2012 to the date of this report

COMPANY'S POLICY ON PAYMENT OF CREDITORS

The company settles its purchase invoices in accordance with the payment terms agreed with the suppliers. The normal policy is to pay invoices promptly and within the normal 30 days.

STATEMENT OF DIRECTOR'S RESPONSIBILITIES

The director is responsible for preparing the Report of the Director and the financial statements in accordance with applicable law and regulations

Company law requires the director to prepare financial statements for each financial year. Under that law the director has elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law the director must not approve the financial statements unless he is satisfied that they give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period. In preparing these financial statements, the director is required to

- select suitable accounting policies and then apply them consistently,
- make judgements and accounting estimates that are reasonable and prudent,
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business

The director is responsible for keeping adequate accounting records that are sufficient to show and explain the company's transactions and disclose with reasonable accuracy at any time the financial position of the company and enable him to ensure that the financial statements comply with the Companies Act 2006. He is also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

STATEMENT AS TO DISCLOSURE OF INFORMATION TO AUDITORS

So far as the director is aware, there is no relevant audit information (as defined by Section 418 of the Companies Act 2006) of which the company's auditors are unaware, and he has taken all the steps that he ought to have taken as a director in order to make himself aware of any relevant audit information and to establish that the company's auditors are aware of that information

Report of the Director for the Year Ended 31 December 2012

AUDITORS

The auditor, Bentleys Chartered Accountants, will be proposed for re-appointment at the forthcoming Annual General Meeting

ON BEHALF OF THE BOARD

Jhanes C Jug Mr Thomas Craig Freyman - Director

Date 27/03/2013

Report of the Independent Auditors to the Members of Starlims Europe Limited

We have audited the financial statements of Starlims Europe Limited for the year ended 31 December 2012 on pages seven to thirteen. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

This report is made solely to the company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in a Report of the Auditors and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members as a body, for our audit work, for this report, or for the opinions we have formed

Respective responsibilities of director and auditors

As explained more fully in the Statement of Director's Responsibilities set out on page three, the director is responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view. Our responsibility is to audit and express an opinion on the financial statements in accordance with applicable law and International Standards on Auditing (UK and Ireland). Those standards require us to comply with the Auditing Practices Board's Ethical Standards for Auditors.

Scope of the audit of the financial statements

An audit involves obtaining evidence about the amounts and disclosures in the financial statements sufficient to give reasonable assurance that the financial statements are free from material misstatement, whether caused by fraud or error. This includes an assessment of whether the accounting policies are appropriate to the company's circumstances and have been consistently applied and adequately disclosed, the reasonableness of significant accounting estimates made by the director, and the overall presentation of the financial statements. In addition, we read all the financial and non-financial information in the Report of the Director to identify material inconsistencies with the audited financial statements. If we become aware of any apparent material misstatements or inconsistencies we consider the implications for our report.

Opinion on financial statements

In our opinion the financial statements

- give a true and fair view of the state of the company's affairs as at 31 December 2012 and of its profit for the year then ended.
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice, and
- have been prepared in accordance with the requirements of the Companies Act 2006

Opinion on other matter prescribed by the Companies Act 2006

In our opinion the information given in the Report of the Director for the financial year for which the financial statements are prepared is consistent with the financial statements

Report of the Independent Auditors to the Members of Starlims Europe Limited

Matters on which we are required to report by exception

We have nothing to report in respect of the following matters where the Companies Act 2006 requires us to report to you if, in our opinion

- adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us, or
- the financial statements are not in agreement with the accounting records and returns, or
- certain disclosures of director's remuneration specified by law are not made, or
- we have not received all the information and explanations we require for our audit

JOHN JOSEPH SHAW BA(Hons) FCA DChA (Senior Statutory Auditor)

for and on behalf of Bentleys **Chartered Accountants** Statutory Auditor Hazlemere 70 Chorley New Road **Bolton**

Lancashire BL1 4BY

Date

27/03/2013

Profit and Loss Account for the Year Ended 31 December 2012

	Notes	2012 £	2011 £
TURNOVER	2	2,335,951	2,712,264
Raw materials and consumables		(400,770)	(1,078,548)
Staff costs Depreciation Other operating charges	3	(1,310,991) (20,853) (519,151)	(1,004,074) (11,691) (508,578)
OPERATING PROFIT	4	84,186	109,373
Interest receivable and similar income		92	62
		84,278	109,435
Interest payable and similar charges	5	(466)	
PROFIT ON ORDINARY ACTIVITIES BEFORE TAXATION		83,812	109,435
Tax on profit on ordinary activities	6	(23,561)	(25,029)
PROFIT FOR THE FINANCIAL YEAR		60,251	84,406
Retained profit brought forward		268,808	184,402
		329,059	268,808
RETAINED PROFIT CARRIED FORWA	ARD	329,059	268,808

CONTINUING OPERATIONS

None of the company's activities were acquired or discontinued during the current year or previous year

TOTAL RECOGNISED GAINS AND LOSSES

The company has no recognised gains or losses other than the profits for the current year or previous year

Balance Sheet 31 December 2012

	Notes	2012 £	2011 £
FIXED ASSETS Tangible assets	7	226,851	29,341
CURRENT ASSETS Debtors Cash at bank	8	582,587 393,620	1,488,380 313,201
		976,207	1,801,581
CREDITORS Amounts falling due within one y	year 9	(863,946)	(1,552,061)
NET CURRENT ASSETS		112,261	249,520
TOTAL ASSETS LESS CURRE	INT LIABILITIES	339,112	278,861
CAPITAL AND RESERVES			
Called up share capital	12	8,400	8,400
Capital redemption reserve	13	1,653	1,653
Profit and loss account		329,059	268,808
SHAREHOLDERS' FUNDS	17	339,112	278,861

The financial statements were approved by the director on

27/03/2013

and were signed by

Mr Thomas Craig Freyman - Director

Notes to the Financial Statements for the Year Ended 31 December 2012

ACCOUNTING POLICIES

Accounting convention

The financial statements have been prepared under the historical cost convention

Financial Reporting Standard Number 1

Exemption has been taken from preparing a cash flow statement on the grounds that the parent company includes the subsidiary in it's published financial statements

Turnover represents net invoiced sales of goods, excluding value added tax, except in respect of service contracts where turnover is recognised when the company obtains the right to consideration

Tangible fixed assets

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life

Leasehold Improvements

- Straight line over 7 years

Office equipment

- Straight line over 7 years

Fixtures and fittings

- Straight line over 7 years

Computer equipment

- 33% on cost

Deferred tax

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date

Foreign currencies

Assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate of exchange ruling at the date of transaction. Exchange differences are taken into account in arriving at the operating result

Hire purchase and leasing commitments

Rentals paid under operating leases are charged to the profit and loss account on a straight line basis over the period of the lease

Pension costs and other post-retirement benefits

The company operates a defined contribution pension scheme Contributions payable to the company's pension scheme are charged to the profit and loss account in the period to which they relate

TURNOVER 2

The turnover and profit before taxation are attributable to the one principal activity of the company

STAFF COSTS 3

	2012 £	2011 £
Wages and salaries	1,052,134	801,037
Social security costs	97,978	80,857
Other pension costs	160,879	122,180
	1,310,991	1,004,074

Notes to the Financial Statements - continued for the Year Ended 31 December 2012

3	STAFF COSTS - continued		
	The average monthly number of employees during the year was as follows	2012	2011
	Technical consultants & programmers Training Sales & Marketing Research & Development Admin	15 3 3 1 3 —————————————————————————————	14 1 2 2 2 2
4	OPERATING PROFIT		
	The operating profit is stated after charging/(crediting)		
	Other operating leases Depreciation - owned assets Auditors' remuneration Foreign exchange differences Auditors' remuneration - non audit services Rent paid	2012 £ 58,836 20,823 6,665 26,543 91,780	2011 £ 53,131 12,423 4,650 (30,182) 2,791 81,885
	Director's remuneration	-	
5	INTEREST PAYABLE AND SIMILAR CHARGES	2012 £	2011 £
	Corporation tax interest	466 ———	
6	TAXATION		
	Analysis of the tax charge The tax charge on the profit on ordinary activities for the year was as follows	2012 £	2011 £
	Current tax UK corporation tax Over/under provision of corporation tax in respect of	13,379	32,483
	prior year	4,882	(5,110)
	Total current tax	18,261	27,373
	Deferred tax	5,300	(2,344)

Tax on profit on ordinary activities

25,029

23,561

Notes to the Financial Statements - continued for the Year Ended 31 December 2012

7	TANGIBL	E FIXED	ASSETS
---	---------	---------	--------

1	I ANGIBLE FIXED ASSET	3		F		
		Leasehold Improvements £	Office equipment £	Fixtures and fittings £	Computer equipment £	Totals £
	COST At 1 January 2012 Additions	139,230	6,942 10,536	1,060 40,515	90,727 28,052	98,729 218,333
	At 31 December 2012	139,230	17,478	41,575	118,779	317,062
	DEPRECIATION At 1 January 2012 Charge for year	1,612	6,194 322	1,060 174	62,134 18,715	69,388 20,823
	At 31 December 2012	1,612	6,516	1,234	80,849	90,211
	NET BOOK VALUE At 31 December 2012	137,618	10,962	40,341	37,930	226,851
	At 31 December 2011		748	-	28,593	29,341
8	DEBTORS AMOUNTS FA	ALLING DUE WIT	HIN ONE YEA	R	2012 £	2011 £
	Trade debtors Other debtors Deferred tax asset Prepayments and accrued	ıncome			537,568 5,466 2,441 37,112	1,458,934 - 7,741 21,705
					582,587	1,488,380
9	CREDITORS AMOUNTS	FALLING DUE W	ITHIN ONE YE	EAR	2012	2011
	Trade creditors Amounts owed to group un Tax Social security and other to Payments on account Accruals & deferred incom	exes			£ 19,265 361,451 13,379 35,663 39,150 395,038	£ 9,913 964,940 32,483 48,870 495,855
					863,946	1,552,061

Notes to the Financial Statements - continued for the Year Ended 31 December 2012

10 OPERATING LEASE COMMITMENTS

The following operating lease payments are committed to be paid within one year

		Land and buildings		Other operating leases	
	Evolano	2012 £	2011 £	2012 £	2011 £
	Expiring Within one year Between one and five years	72,196	90,516	12,996 30,469	6,578 43,445
		72,196	90,516	43,465	50,023
11	DEFERRED TAX				£
	Balance at 1 January 2012 Provided during year				(7,741) 5,300
	Balance at 31 December 2012				(2,441) =====

The recognition of the deferred tax asset is supported by management's forecasts of the future profitability of the business

12 CALLED UP SHARE CAPITAL

	Number	ued and fully paid Class	Nominal value	2012 £	2011 £
	8,400	Ordinary	£1	8,400	8,400
13	RESERVES	•			Capital redemption reserve £

14 ULTIMATE PARENT COMPANY

At 1 January 2012

At 31 December 2012

Abbott Laboratories (incorporated in the USA) is regarded by the director as being the company's ultimate parent company

Abbott Laboratories is listed on the New York Stock Exchange and the London Stock Exchange

15 RELATED PARTY DISCLOSURES

The company is wholly owned by its parent company and has taken advantage of the exemption in FRS 8 Related Party Disclosures to not disclose transactions with its parent company and other wholly owned subsidiaries within the group

Page 12

continued

1,653

1,653

Notes to the Financial Statements - continued for the Year Ended 31 December 2012

16 ULTIMATE CONTROLLING PARTY

The ultimate controlling party is Abbott Laboratories (incorporated in the USA)

17 RECONCILIATION OF MOVEMENTS IN SHAREHOLDERS' FUNDS

	2012 £	2011 £
Profit for the financial year	60,251	84,406
Net addition to shareholders' funds Opening shareholders' funds	60,251 278,861	84,406 194,455
Closing shareholders' funds	339,112	278,861

Trading and Profit and Loss Account for the Year Ended 31 December 2012

	2012		2011		
	£		£	£	£
Sales			2,335,951		2,712,264
Cost of sales Purchases		_	400,770		1,078,548
GROSS PROFIT			1,935,181		1,633,716
Other income Deposit account interest			92		62
		_	1,935,273		1,633,778
Expenditure Rent Rates and water Wages Social security Pensions Vehicle leasing charges Telephone Post and stationery Marketing and promotion Travelling Motor expenses Insurance Repairs and renewals Computer related Medical cover Sundry expenses Training costs Legal and professional fees Auditors' remuneration Foreign exchange (gains) / losses Bad debts	91,78 6,38 ,052,13 97,97 160,87 58,83 30,06 2,06 6,38 177,31 41,73 1,56 9,12 18,33 8,97 3,41 46,73 6,66 26,54 (19,60	39 34 79 36 37 39 99 18 38 99 18 37 76 37 36 37 37 36 37 37 36 37 37 37 37 37 37 37 37 37 37 37 37 37	1,827,744	81,885 12,552 801,037 80,857 122,180 53,131 26,822 4,645 102,132 123,359 34,809 1,433 385 7,020 11,473 10,519 5,621 45,647 4,650 (30,182) 10,500	1,510,475 123,303
Finance costs Bank charges Corporation tax interest	2,39 46			2,177	
_		_ 	2,864	e san	2,177
			104,665		121,126
Depreciation Depreciation		_	20,853		11,691
NET PROFIT		=	83,812		109,435